Latest Period
Q2 2026
Security Snapshot
Ultragenyx Pharmaceutical Inc. - Common Stock, $0.001 par value (RARE) Institutional Ownership
CUSIP: 90400D108
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
308
Shares (Excl. Options)
106,558,548
Price
$33.39
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- RARE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 106,558,548
- Total 13F value
- $3,546,830,247
- Portfolio coverage rank
- 0%
- Share change
- +8,571,757
- Value change
- +$343,924,327
- Number of holders
- 308
- Shares outstanding
- 98,694,873
- SEC-reported price per share
- $25.00
- Insider filing price
- $25.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RARE - Ultragenyx Pharmaceutical Inc. - Common Stock, $0.001 par value is tracked under CUSIP 90400D108.
- 308 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 295 to 308 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,053,869,165 to $3,546,830,247.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 308 institutions filings for Q2 2026.
Security key
90400D108
Latest holder period
Q2 2026
13F holders
308
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
RARE full holder history
Ultragenyx Pharmaceutical Inc. SEC filings
Ultragenyx Pharmaceutical Inc. company facts
Ultragenyx Pharmaceutical Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90400D108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
RARE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 8.3% | +64% | $271,840,812 | +$110,869,926 | 8,141,384 | +69% | BlackRock, Inc. | 30 Jun 2026 |
| RTW INVESTMENTS, LP | 7.9% | $260,338,324 | 7,796,895 | RTW Investments, LP | 30 Jun 2026 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7% | +24% | $228,835,928 | +$48,189,082 | 6,853,427 | +27% | Vanguard Portfolio Management | 30 Jun 2026 |
| AQR CAPITAL MANAGEMENT LLC | 6.7% | $219,065,413 | 6,560,809 | AQR Capital Management, LLC | 30 Jun 2026 | |||
| STATE STREET CORP | 6.3% | +24% | $205,641,197 | +$37,975,282 | 6,158,766 | +23% | STATE STREET CORPORATION | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $168,900,610 | 5,058,419 | Vanguard Capital Management | 30 Jun 2026 | |||
| SANDS CAPITAL MANAGEMENT, LLC | 4.7% | $163,238,154 | 4,298,003 | SANDS CAPITAL MANAGEMENT, LLC | 31 Dec 2024 | |||
| FMR LLC | 3.5% | -60% | $77,001,475 | -$106,192,081 | 3,347,890 | -58% | FMR LLC | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.7% | $93,337,483 | 2,457,543 | Wellington Management Group LLP | 31 Dec 2024 |
As of 30 Jun 2026, 308 institutional investors reported holding 106,558,548 shares of Ultragenyx Pharmaceutical Inc. - Common Stock, $0.001 par value (RARE). This represents 108% of the company’s total 98,694,873 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
78%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | 10,654,276 | +46% | 0.01% | $355,746,262 |
| RTW INVESTMENTS, LP | 7.9% | 7,796,895 | +114% | 2.2% | $260,338,324 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.9% | 6,790,135 | +26% | 0.01% | $226,722,608 |
| AQR CAPITAL MANAGEMENT LLC | 6.6% | 6,560,809 | +43% | 0.07% | $214,144,806 |
| STATE STREET CORP | 6.2% | 6,158,766 | +23% | 0.01% | $205,641,197 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 4,296,491 | +2.5% | 0% | $143,459,834 |
| TWO SIGMA INVESTMENTS, LP | 3.7% | 3,621,200 | +64% | 0.09% | $120,911,868 |
| SANDS CAPITAL MANAGEMENT, LLC | 3.2% | 3,158,368 | -1.7% | 0.39% | $105,457,908 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3% | 2,939,719 | +105% | 0.35% | $98,157,217 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 2.9% | 2,847,936 | +30% | 0.89% | $95,092,590 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 2,578,828 | +39% | 0% | $86,123,888 |
| Bellevue Group AG | 2% | 1,982,775 | -17% | 1.4% | $66,204,857 |
| D. E. Shaw & Co., Inc. | 1.8% | 1,730,193 | +37% | 0.04% | $57,771,145 |
| Sofinnova Investments, Inc. | 1.7% | 1,717,505 | -45% | 3.1% | $57,347,492 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.6% | 1,580,000 | +229% | 0.07% | $52,756,200 |
| GW&K Investment Management, LLC | 1.5% | 1,481,178 | -8.3% | 0.39% | $49,457,000 |
| MPM BIOIMPACT LLC | 1.4% | 1,418,215 | 2.9% | $47,354,199 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 1,356,501 | +69% | 0% | $45,295,000 |
| MORGAN STANLEY | 1.3% | 1,324,805 | -12% | 0% | $44,235,265 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.3% | 1,250,464 | -53% | 0.01% | $41,752,993 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.3% | 1,241,556 | -13% | 0.18% | $41,455,555 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 1,148,454 | +9.7% | 0% | $38,346,863 |
| Candriam S.C.A. | 1% | 1,001,841 | -8.6% | 0.15% | $33,419,286 |
| Rock Springs Capital Management LP | 0.98% | 967,855 | -21% | 1.6% | $32,316,678 |
| Jefferies Financial Group Inc. | 0.94% | 929,626 | +5902% | 0.29% | $31,040,212 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 106,558,548 | $3,546,830,247 | +$343,924,327 | $33.39 | 308 |
| 2026 Q1 | 98,123,750 | $2,053,869,165 | +$63,722,429 | $20.95 | 295 |
| 2025 Q4 | 93,873,177 | $2,157,035,170 | -$88,987,931 | $23.00 | 286 |
| 2025 Q3 | 95,480,928 | $2,872,333,685 | -$30,390,841 | $30.08 | 301 |
| 2025 Q2 | 94,131,376 | $3,423,160,510 | +$191,188,547 | $36.36 | 307 |
| 2025 Q1 | 88,841,861 | $3,218,915,813 | +$30,616,617 | $36.21 | 297 |
| 2024 Q4 | 87,497,812 | $3,681,153,433 | +$1,949,206 | $42.07 | 309 |
| 2024 Q3 | 86,896,233 | $4,824,969,188 | -$72,319,917 | $55.55 | 299 |
| 2024 Q2 | 88,212,580 | $3,625,598,894 | +$337,028,289 | $41.10 | 273 |
| 2024 Q1 | 79,925,459 | $3,729,060,008 | -$19,184,689 | $46.69 | 268 |
| 2023 Q4 | 80,397,353 | $3,844,802,509 | +$498,492,380 | $47.82 | 236 |
| 2023 Q3 | 70,612,041 | $2,517,056,820 | +$10,459,486 | $35.65 | 219 |
| 2023 Q2 | 69,514,116 | $3,206,303,623 | +$38,331,356 | $46.13 | 239 |
| 2023 Q1 | 68,735,803 | $2,755,924,776 | +$28,159,264 | $40.10 | 227 |
| 2022 Q4 | 68,068,127 | $3,153,029,340 | +$13,205,113 | $46.33 | 225 |
| 2022 Q3 | 67,920,512 | $2,812,302,784 | -$149,070,496 | $41.41 | 223 |
| 2022 Q2 | 67,540,585 | $4,030,154,883 | +$24,063,212 | $59.66 | 210 |
| 2022 Q1 | 67,087,441 | $4,870,684,649 | -$37,258,962 | $72.62 | 227 |
| 2021 Q4 | 67,646,883 | $5,688,385,130 | +$80,515,709 | $84.09 | 224 |
| 2021 Q3 | 66,666,465 | $6,012,124,489 | +$97,920,619 | $90.19 | 217 |
| 2021 Q2 | 65,481,898 | $6,240,143,536 | -$246,149,121 | $95.35 | 235 |
| 2021 Q1 | 67,877,270 | $7,730,039,829 | +$45,641,218 | $113.86 | 244 |
| 2020 Q4 | 67,658,657 | $9,366,525,048 | +$640,902,584 | $138.43 | 247 |
| 2020 Q3 | 63,092,193 | $5,187,430,003 | -$8,503,385 | $82.19 | 199 |
| 2020 Q2 | 63,208,158 | $4,944,359,312 | +$242,670,060 | $78.22 | 185 |